Shanghai Bio-heart Biological Technology (HKG:2185) delayed the dispatch of a circular regarding the disposal of a 45.3% stake in Zhejiang Bioheart Medical Equipment to Jan. 27, a Friday Hong Kong bourse filing said.
The interventional cardiovascular device company needs additional time to finalize certain information to be included in the circular.
The firm is selling the stake to Jiaxing Guojian Baixin Equity Investment Partnership Enterprise in exchange for a 155.6 million yuan capital injection in the unit, according to a Jan. 2 disclosure.